MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000545001

Медицинская библиотека · Oncology · 2025

Modified Glasgow Prognostic Score as a Marker for Predicting Outcomes in Patients with either Bladder or Prostate Cancer: A Systematic Review and Meta-Analysis.

Chen Jie, Fu Suna, Yu Jianhong, Tang Qi, Wu Xiuping, Luo Sai, Sun Huifang

Систематический обзорСтатьяМетаанализПеревод в очереди

Аннотация

INTRODUCTION

The aim of this study was to investigate the association of pre-treatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC).

METHODS

A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS, and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random-effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7).

RESULTS

Of 20 studies included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR: 2.65; 95% CI: 1.99, 3.52), CSS (HR: 1.64; 95% CI: 1.19, 2.26), and RFS (HR: 1.77; 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger's p > 0.05). These associations remained valid in subgroup analysis.

CONCLUSION

Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.

Для цитирования: Chen Jie, Fu Suna, Yu Jianhong, Tang Qi, Wu Xiuping, Luo Sai, Sun Huifang. Modified Glasgow Prognostic Score as a Marker for Predicting Outcomes in Patients with either Bladder or Prostate Cancer: A Systematic Review and Meta-Analysis.. Oncology. 2025. DOI: 10.1159/000545001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.